Factors Influencing a Specific Pathologic Diagnosis of Non-Small-Cell Lung Carcinoma

被引:6
作者
Sulpher, Jeffrey A. [1 ]
Owen, Scott P. [2 ]
Hon, Henrique [2 ]
Tobros, Kimberly [2 ]
Shepherd, Frances A. [2 ]
Sabri, Elham [3 ]
Gomes, Marcio [4 ]
Sekhon, Harman [4 ]
Liu, Geoffrey [2 ]
Canil, Christina M. [1 ]
Wheatley-Price, Paul [1 ]
机构
[1] Univ Ottawa, Dept Med, Ottawa Hosp, Ctr Canc, Ottawa, ON, Canada
[2] Univ Toronto, Univ Hlth Network, Princess Margaret Hosp, Div Med Oncol & Hematol,Dept Med, Toronto, ON M5S 1A1, Canada
[3] Univ Ottawa, Res Inst, Ottawa Hosp, Ottawa, ON, Canada
[4] Univ Ottawa, Dept Pathol & Lab Med, Ottawa Hosp, Ottawa, ON, Canada
关键词
Chart review; Diagnosis; Histology; Non-small-cell lung cancer; CANCER; CHEMOTHERAPY; MUTATIONS; GEFITINIB; CYTOLOGY; EGFR; ADENOCARCINOMA; CLASSIFICATION; CARBOPLATIN; PACLITAXEL;
D O I
10.1016/j.cllc.2012.11.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pathologic subtyping of non-small-cell lung carcinoma is increasingly important when selecting therapy. The records of 739 patients were reviewed to identify factors associated with attaining a specific pathologic diagnosis. Only 456 (62%) of patients received a specific pathologic diagnosis, which was significantly associated with histologic biopsy samples, immunohistochemical testing, and diagnosis outside of an academic center. Introduction: Historically, a non-small-cell lung carcinoma diagnosis, without pathologic subclassification, provided sufficient information to guide therapy. Evidence now demonstrates that pathologic subtype classification is central in selecting optimal treatment. This review aimed to identify factors associated with a specific pathologic diagnosis. Methods: All nonoperative cases of non-small-cell lung carcinoma (NSCLC) referred to the medical oncology divisions of the Ottawa Hospital Cancer Centre (2008) and Princess Margaret Hospital, Toronto (2007-2010) were identified. The charts were reviewed for demographics, diagnostic methods, and final diagnosis. Logistic regression was performed to identify variables associated with a specific diagnosis. Results: Of 739 patient records analyzed, 377 (51%) were men, 299 (40%) were aged over 70 years, and 510 (69%) had an Eastern Cooperative Oncology Group performance status of 0-2. Three hundred and eighty five (52%) of patients were diagnosed in a tertiary academic center. The lung primary was sampled in 503 (68%) of patients. Computed tomography-guided biopsy (n = 370, 50%) and bronchoscopy (n = 179, 24%) were the most common techniques. Four hundred and seventy seven (65%) of biopsies were cytologic specimens alone, and immunohistochemistry was performed in 337 (46%) of cases. The most common diagnoses were adenocarcinoma (n = 338, 46%), NSCLC not otherwise specified (n = 254, 34%), and squamous cell carcinoma (n = 115, 16%). Overall, 456 (62%) of patients received a specific pathologic diagnosis. Factors significantly associated with attaining a specific pathologic diagnosis were diagnosis outside an academic center (adjusted odds ratios [OR] 2.1 [95% CI, 1.41-3.14]; P = .0003), histologic laboratory samples (adjusted OR 1.58 [95% CI, 1.003-2.49]; P = .049), and immunohistochemical testing (adjusted OR 1.82 [95% CI, 1.25-2.70], P = .0021). Conclusions: A significant minority of patients with NSCLC do not receive a specific pathologic diagnosis. In an era of individualized medicine, this may potentially impact optimal clinical management. Clinical Lung Cancer, Vol. 14, No. 3, 238-44 (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:238 / 244
页数:7
相关论文
共 50 条
  • [21] Molecular pathological diagnosis in cytopathology of non-small-cell lung cancer. Standardization of specimen processing
    Warth, A.
    Bubendorf, L.
    Gutz, S.
    Morresi-Hauf, A.
    Hummel, M.
    Junker, K.
    Lehmann, U.
    Petersen, I.
    Schnabel, P. A.
    PATHOLOGE, 2013, 34 (04): : 310 - 317
  • [22] Molecular pathological diagnosis in cytopathology of non-small-cell lung cancer. Standardization of specimen processing
    Warth, A.
    Bubendorf, L.
    Gutz, S.
    Morresi-Hauf, A.
    Hummel, M.
    Junker, K.
    Lehmann, U.
    Petersen, I.
    Schnabel, P. A.
    PATHOLOGE, 2013, 34 (04): : 310 - 317
  • [23] Favorable clinical outcomes of pemetrexed treatment in anaplastic lymphoma kinase positive non-small-cell lung cancer
    Lee, Ha Yeon
    Ahn, Hee Kyung
    Jeong, Ji Yun
    Kwon, Mi Jung
    Han, Jung-Ho
    Sun, Jong-Mu
    Ahn, Jin Seok
    Park, Keunchil
    Choi, Yoon-La
    Ahn, Myung-Ju
    LUNG CANCER, 2013, 79 (01) : 40 - 45
  • [24] Cetuximab in non-small-cell lung cancer
    Carillio, Guido
    Montanino, Agnese
    Costanzo, Raffaele
    Sandomenico, Claudia
    Piccirillo, Maria Carmela
    Di Maio, Massimo
    Daniele, Gennaro
    Giordano, Pasqualina
    Bryce, Jane
    Normanno, Nicola
    Rocco, Gaetano
    Perrone, Francesco
    Morabito, Alessandro
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (02) : 163 - 175
  • [25] Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis
    Chen, Yan
    Wang, Mengzhao
    Zhong, Wei
    Zhao, Jing
    LUNG CANCER, 2013, 82 (02) : 313 - 318
  • [26] The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer
    Neal, Joel W.
    FUTURE ONCOLOGY, 2010, 6 (12) : 1827 - 1832
  • [27] Integration of EGFR Inhibitors and Conventional Chemotherapy in the Treatment of Non-Small-cell Lung Cancer
    Pennell, Nathan A.
    CLINICAL LUNG CANCER, 2011, 12 (06) : 350 - 359
  • [28] Bevacizumab for non-small-cell lung cancer: A nested case control study of risk factors for hemoptysis
    Goto, Koichi
    Endo, Masahiro
    Kusumoto, Masahiko
    Yamamoto, Nobuyuki
    Ohe, Yuichiro
    Shimizu, Ayaka
    Fukuoka, Masahiro
    CANCER SCIENCE, 2016, 107 (12) : 1837 - 1842
  • [29] The role of afatinib in the management of non-small cell lung carcinoma
    Yap, Timothy A.
    Popat, Sanjay
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2013, 9 (11) : 1529 - 1539
  • [30] Whole brain radiotherapy in management of non-small-cell lung carcinoma associated leptomeningeal carcinomatosis: evaluation of prognostic factors
    Ozdemir, Yurday
    Yildirim, Berna Akkus
    Topkan, Erkan
    JOURNAL OF NEURO-ONCOLOGY, 2016, 129 (02) : 329 - 335